By enhancing clinical standards these partnerships empower ICPO Centers to achieve better patient outcomes and expanding access to radiotheranostics.
June 24, 2025 – Wiesbaden, Germany. The International Centers for Precision Oncology (ICPO) Foundation announced the cooperation with four new ICPO Clinical Theranostics Centers of Excellence (CoE) in Bangalore (India), New Delhi (India), Amman (Jordan) as well as in Umhlanga (South Africa) to improve clinical practice as well as patient-focused processes and drive innovation with radiotheranostics. All ICPO CoEs will promote the ICPO Academy for Theranostics in their countries, training healthcare professionals. At the same time, the ICPO Foundation will provide each center with international visibility within the ICPO community. Previously, ICPO CoEs had been successfully established in Australia, Azerbaijan, China, Dubai, Egypt, Germany, India, Mexico, the Philippines, South Africa, Turkey, and Uruguay, continuously expanding the network.
Odile Jaume, CEO of the ICPO Foundation, commented: "We are delighted to welcome four new ICPO Clinical Centers of Excellence from three different regions into our ICPO network. This expansion strengthens global collaboration in radiotheranostics and reflects growing trust in ICPO's standards, best practices, and services. By uniting expertise across our community, we move closer to treating more cancer patients with radiotheranostics and improving patient outcomes worldwide."
The following theranostics centers represented by their directors have joined the ICPO Clinical Theranostics Center of Excellence network:
Aster Whitefield Hospital in Bangalore, India;
Dr. Prathap H. J., Head of Nuclear Medicine & Theranostics Department
Aster Whitefield's Theragnostic Center has demonstrated a steady increase in both diagnostic and therapeutic services. The center performs approximately 150 diagnostic PET/CT scans per month, along with 10-12 therapeutic procedures each month, including targeted radionuclide therapies and FAPI treatments. The center has completed multiple FAPI therapies, including innovative combinations of FAPI-DOTA and FAPI-PSMA therapies. Ongoing training for staff in radiation safety, radiopharmaceutical handling, and patient care ensures the highest level of service.
The Rajiv Gandhi Cancer Institute & Research Centre (RGCIRC) in New Delhi, India
Dr. Partha Choudhary, Director of Nuclear Medicine
The Rajiv Gandhi Cancer Institute & Research Centre (RGCIRC), established in 1996 by the Indraprastha Cancer Society and Research Centre under the Societies Registration Act of 1860, is a not-for-profit institution committed to delivering high-quality, accessible, and affordable cancer care. As one of Asia's leading oncology centers, RGCIRC integrates advanced medical technologies and expertise to serve patients from India and neighboring regions, providing comprehensive diagnostic and therapeutic services.
King Hussein Cancer Center (KHCC) in Amman, Jordan
Dr. Akram Al-Ibraheem, Chairman of the Nuclear Medicine Department
KHCC is the only specialized cancer center in the Middle East that provides comprehensive care to both adult and pediatric patients. Its Department of Nuclear Medicine is a regional pioneer, offering advanced diagnostics and therapeutic services for cancer patients through nuclear, molecular, and biological technologies. The department's vision is to promote precision medicine in Jordan and the region by empowering molecular radionuclide diagnostics and therapy.
Umhlanga Molecular Imaging & Therapy Centre in Umhlanga, South Africa
Dr. Masha Maharaj, Head of Nuclear Medicine Department
The Umhlanga Molecular Imaging & Therapy Centres of Excellence, established in 2014, has emerged as a key provider of specialized nuclear medicine services in Southern Africa. With operational sites across KwaZulu-Natal, South Africa, and Lagos, Nigeria, the center offers a broad range of diagnostic and therapeutic services tailored to the evolving demands of precision oncology.
Application for the network of ICPO Clinical Theranostics Centers of Excellence
The ICPO Foundation offers a structured accreditation pathway that recognizes centers' current achievements and provides a clear roadmap toward future development. Theranostics centers can join the ICPO Clinical Centers of Excellence Network using the application form on our website: www.icpo.foundation/icpo-centers/application/
Press photo: Photos of the new ICPO Clinical Centers of Excellence in India, Jordan and South Africa
About ICPO Foundation
The International Centers for Precision Oncology Foundation (ICPO) is a non-profit organization established in 2019 under German law by leading international medical practitioners and life sciences entrepreneurs. Recognizing a paradigm shift in cancer care from one size fits all to a personalized approach, the ICPO Foundation is helping to build momentum to scale global patient access to Radiomolecular Precision Oncology to support this shift. Therefore, the ICPO Foundation aims to develop an international network of physical diagnostic and therapeutic Centers for Precision Oncology based on a model of shared know-how, of certified education with the ICPO Academy for Theranostics, and of design and process standardization that enables best clinical practice globally. Furthermore, it is the ICPO Foundation's objective to empower its centers by embedding them in a highly inclusive community that spearheads its model and lives up to the precision oncology promise by making it available to all patients in need, irrespective of country or social status.
Learn more about the ICPO Foundation at www.icpo.foundation and the ICPO Academy for Theranostics at www.theranostics.academy
Media contact ICPO Foundation
Susanne Simon, Head of Communication & Community
Email: susanne.simon@icpo.foundation, Phone: + 49 172 8666093, Website: www.icpo.foundation
Please download this press release here.